Advertisement

Topics

Latest "Forest Laboratories, Inc. and Clinical Data, Inc." News Stories

00:33 EDT 26th September 2018 | BioPortfolio

Here are the most relevant search results for "Forest Laboratories, Inc. and Clinical Data, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Forest Laboratories, Inc. and Clinical Data, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Forest Laboratories, Inc. and Clinical Data, Inc. for you to read. Along with our medical data and news we also list Forest Laboratories, Inc. and Clinical Data, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Forest Laboratories, Inc. and Clinical Data, Inc. Companies for you to search.

Showing "Forest Laboratories Clinical Data" News Articles 1–25 of 35,000+

Tuesday 25th September 2018

Micell Technologies Inc Medical Equipment Deals and Alliances Profile [Report Updated: 16052018] Prices from USD $250

SummaryMicell Technologies Inc Micell is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company offers product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drugeluting stent that is designed to optimize healing. It provides novel drugcoated balloon to deliver sirolimus to the artery wall at the site of...


Foundation Radiology Group PC Medical Equipment Deals and Alliances Profile [Report Updated: 16052018] Prices from USD $250

SummaryFoundation Radiology Group PC FRG is a radiology solutions provider. The company provides radiological services in areas of pediatric, neurology, mammography, musculoskeletal, PET and CT, cardiac CT and interventional radiology. It provides imaging solutions for the radiologists and systems to the existing radiology department. FRG's solutions include programmatic strategic alignment, multi...

Big-data project aims to transform farming in world’s poorest countries


PeptiDream Announces Drug Discovery and Development Agreement with Santen Pharmaceutical

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a broad-based multi-target discovery and development agreement with Osaka-based Santen Pharmaceuticals Co., Ltd., (“Santen”). Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform Syste...

Evolve Biologics™ Provides Update on Progress in Phase III Trial for PlasmaCap™ IG (Intravenous Immunoglobulin)

More than 80% of Required Infusions Now Successfully Administered in Adult Portion of Study Recruitment and Enrollment of Patients in Pediatric Portion of Study Continues to Proceed On Plan Abstracts on the Study and PlasmaCap EBA™ Technology Accepted for Presentation at Upcoming Immunoglobulin National Society (“IgNS”) Confe...

AKCA Up 33% In 2 Days, AGTC Awaits XLRS Data, EYPT On Watch

The following are some of today's top gainers in the pharma/biotech sector.

Agilent to Expand Portfolio and Capabilities in Cell Analysis with Acquisition of ACEA Biosciences

Highlights: Acquisition adds a differentiated portfolio and organizational capabilities in the fast-growing cell analysis market Combined portfolio expands cell-based applications and workflows allowing customers more choices to answer more questions from a single sample Combined clinical reagent...

Fresenius Kidney Care Medical Equipment Deals and Alliances Profile [Report Updated: 16052018] Prices from USD $250

SummaryFresenius Kidney Care FMCNA , formerly Fresenius Medical Care Holdings Inc, a subsidiary of Fresenius Medical Care AG Co KGaA, is a provider of dialysis services and renal care products. The company's dialysis products include hemodialysis; dialyzers, haemodialysis machines, FMiS medical information system, bloodlines and concentrates, home therapy products and others; its home therapy pro...

#jobs #lifescience QC Associate Scientist

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: QC Associate Scientist .NC-Sanford, The position will support the Pfizer Sanford, NC Quality Operations department by performing Quality Control activities associated with clinical and/or commercial product, raw materials, … Continue reading → Cet article #jobs #li...

STAT Plus: A new study "contradicts the idea" that rigorous FDA rules make clinical trials so expensive. "We’re choking off the emergence of dramatic new drugs,” a co-author said. https://buff.ly/2Q6QHfZ 

STAT Plus: A new study "contradicts the idea" that rigorous FDA rules make clinical trials so expensive. "We’re choking off the emergence of dramatic new drugs,” a co-author said. https://buff.ly/2Q6QHfZ 

AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit

AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1.0 million for the year ending 30 June 2017. The R&D Tax Credit incentive program provides a c

Change Without Disruption is Possible

‘Fear of change’ is a powerful force. Many believe that if something truly novel is created, something existing must die. It’s as if innovation is a zero-sum game. Whilst it’s true that change can be disruptive and expensive, there are precious times when change – or rather evolution – is purely constructive. Today, the data marketplace of individual healthcare consumers is broken. It...

QuantuMDx Group Ltd Medical Equipment Deals and Alliances Profile [Report Updated: 12062018] Prices from USD $250

SummaryQuantuMDx Group Ltd QuantuMDx is a medical device company that develops hand held and portable diagnostic, genomic sequencing and proteomic platforms. The company's products comprise QPOC is a handheld DNA analyzer that provides an accurate molecular diagnostic results. It develops assays for diagnosis and drug susceptibility testing of infectious diseases, and companion diagnostics assays ...

MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study 25.09.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, September 25, 2018   MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients   MorphoSys AG (FSE: MOR; Prime Standard Segment, MD...

Free Space Optics and Visible Light Communication /Light Fidelity Market by Component, ...

NEW YORK, Sept. 25, 2018 /PRNewswire/ -- Free licensing and faster and safer data transfer are driving the FSO and VLC markets Read the full Read more...

Hybrid operating room enables faster diagnosis, treatment of patients with lung cancer

Representing a paradigm shift in thoracic surgery, the hybrid operating room combines three techniques into a single appointment eliminating multiple clinical visits for improved patient experience and outcomes.

$ALDX to Announce Results from Phase 2b Dry Eye Disease Clinical Trial tomorrow September 26, 8AM https://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-announce-results-from-phase-2b-dry-eye-disease-clinica

$ALDX to Announce Results from Phase 2b Dry Eye Disease Clinical Trial tomorrow September 26, 8AM https://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-announce-results-from-phase-2b-dry-eye-disease-clinical-trial-300718710.html …

TransContainer (TRCN) - Revenue and cost initiatives paying off

Edison Investment Research - General Industrials - TransContainer: TransContainer (TC) has continued to show strong results, with Q218 EBITDA, reported on 29 August, increasing by 13% y-o-y. The company is benefiting from structural growth, especially switching rail cargo to containers, and Russia’s economic recovery. Recent monthly market data bode well for TC’s Q318 results. It has a...

$LOXO-292 RET data update out at #WCLC2018 -> $BPMC https://ir.loxooncology.com/docs/events/WCLC_2018-LOXO292.PDF … ORR in RET Fusion-Positive NSCLC down a bit to 68% from 77% at ASCO DoR looking good with 24/26 (92%) responses ongoing, 17 responses

$LOXO-292 RET data update out at #WCLC2018 -> $BPMC https://ir.loxooncology.com/docs/events/WCLC_2018-LOXO292.PDF … ORR in RET Fusion-Positive NSCLC down a bit to 68% from 77% at ASCO DoR looking good with 24/26 (92%) responses ongoing, 17 responses ≥6 months pic.twitter.com/y9MpY33yHG

WCLC2018 Roundup of key lung cancer data

There’s a lot going on in lung cancer of late, especially with the World Conference on Lung Cancer (WCLC) taking…

$AUPH Completes Enrollment of AURORA, its P 3 Clinical Trial for the Treatment of Lupus Nephritis. Target enrollment has been exceeded and completed ahead of schedule. Company anticipates primary data analysis in Q4 2019

$AUPH Completes Enrollment of AURORA, its P 3 Clinical Trial for the Treatment of Lupus Nephritis. Target enrollment has been exceeded and completed ahead of schedule. Company anticipates primary data analysis in Q4 2019

STAT Plus: if you missed our webinar on how to interpret clinical trial results, you can watch @sxbegle and @adamfeuerstein's archived presentation here. https://buff.ly/2NDx7vp 

STAT Plus: if you missed our webinar on how to interpret clinical trial results, you can watch @sxbegle and @adamfeuerstein's archived presentation here. https://buff.ly/2NDx7vp 

Former Alnylam Exec Jared Gollob Named Kymera Chief Medical Officer

Jared Gollob has been appointed chief medical officer of Cambridge, MA-based Kymera Therapeutics. Gollob most recently worked at Alynylam Pharmaceuticals (NASDAQ: ALNY) where he was vice president of clinical development and global vice president of medical affairs. Kymera is developing drugs based on protein degradation, the process cells use to rid themselves of harmful proteins.

Genentech Executive Jason Ehrlich Joins Kodiak Sciences C-Suite

Kodiak Sciences has appointed Jason Ehrlich to serve as chief medical officer and chief development officer of the Palo Alto, CA, eye drug developer. Ehrlich comes to Kodiak from Roche subsidiary, Genentech, where he was global head, clinical ophthalmology. Recently, Kodiak filed for an IPO to finance clinical trials testing its lead drug, KSI-301, in […]

Healogics Joins the Epic App Orchard

Healogics Inc., the nation’s largest provider of advanced wound care services, today announced they have joined the App Orchard to begin working on an integration to improve interoperability within their nationwide network of Wound Care Centers®. Currently, this integration is set to deploy in the fall of 2019. This integration will allow discr...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks